IMAGENEBIO INC (IMA) Fundamental Analysis & Valuation

NASDAQ:IMA • US45175G2075

Current stock price

5.63 USD
-0.06 (-1.05%)
Last:

This IMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IMA Profitability Analysis

1.1 Basic Checks

  • In the past year IMA has reported negative net income.
  • IMA had a negative operating cash flow in the past year.
  • IMA had negative earnings in each of the past 5 years.
  • IMA had a negative operating cash flow in each of the past 5 years.
IMA Yearly Net Income VS EBIT VS OCF VS FCFIMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

  • IMA has a Return On Assets of -30.60%. This is comparable to the rest of the industry: IMA outperforms 51.30% of its industry peers.
  • The Return On Equity of IMA (-35.21%) is better than 60.62% of its industry peers.
Industry RankSector Rank
ROA -30.6%
ROE -35.21%
ROIC N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
IMA Yearly ROA, ROE, ROICIMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMA Yearly Profit, Operating, Gross MarginsIMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IMA Health Analysis

2.1 Basic Checks

  • IMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMA Yearly Shares OutstandingIMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IMA Yearly Total Debt VS Total AssetsIMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -0.32, we must say that IMA is in the distress zone and has some risk of bankruptcy.
  • IMA has a Altman-Z score (-0.32) which is comparable to the rest of the industry.
  • There is no outstanding debt for IMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.32
ROIC/WACCN/A
WACC9.42%
IMA Yearly LT Debt VS Equity VS FCFIMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • IMA has a Current Ratio of 13.24. This indicates that IMA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 13.24, IMA belongs to the top of the industry, outperforming 85.49% of the companies in the same industry.
  • IMA has a Quick Ratio of 13.24. This indicates that IMA is financially healthy and has no problem in meeting its short term obligations.
  • IMA has a Quick ratio of 13.24. This is amongst the best in the industry. IMA outperforms 85.49% of its industry peers.
Industry RankSector Rank
Current Ratio 13.24
Quick Ratio 13.24
IMA Yearly Current Assets VS Current LiabilitesIMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IMA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.58% over the past year.
EPS 1Y (TTM)41.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, IMA will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.63% on average per year.
  • The Revenue is expected to grow by 138.32% on average over the next years. This is a very strong growth
EPS Next Y54.35%
EPS Next 2Y26.16%
EPS Next 3Y12.04%
EPS Next 5Y10.63%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y138.32%

3.3 Evolution

IMA Yearly Revenue VS EstimatesIMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2030 2031 2032 2033 100M 200M 300M
IMA Yearly EPS VS EstimatesIMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMA Price Earnings VS Forward Price EarningsIMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMA Per share dataIMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMA's earnings are expected to grow with 12.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.16%
EPS Next 3Y12.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMA Dividend Analysis

5.1 Amount

  • IMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMA Fundamentals: All Metrics, Ratios and Statistics

IMAGENEBIO INC

NASDAQ:IMA (3/23/2026, 5:11:08 PM)

5.63

-0.06 (-1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-10
Earnings (Next)05-06
Inst Owners40.68%
Inst Owner Change6.19%
Ins Owners4.14%
Ins Owner Change43.83%
Market Cap59.96M
Revenue(TTM)N/A
Net Income(TTM)-49.23M
Analysts77.14
Price Target16.32 (189.88%)
Short Float %4.65%
Short Ratio10.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-33.76%
Min EPS beat(2)-125.09%
Max EPS beat(2)57.57%
EPS beat(4)3
Avg EPS beat(4)-12.85%
Min EPS beat(4)-125.09%
Max EPS beat(4)57.57%
EPS beat(8)6
Avg EPS beat(8)0.36%
EPS beat(12)10
Avg EPS beat(12)4.45%
EPS beat(16)12
Avg EPS beat(16)9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-7.08
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-4.4
FCFYN/A
OCF(TTM)-4.4
OCFYN/A
SpS0
BVpS13.13
TBVpS13.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.6%
ROE -35.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.24
Quick Ratio 13.24
Altman-Z -0.32
F-Score3
WACC9.42%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.42%
EPS Next Y54.35%
EPS Next 2Y26.16%
EPS Next 3Y12.04%
EPS Next 5Y10.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y138.32%
EBIT growth 1Y27.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.97%
OCF growth 3YN/A
OCF growth 5YN/A

IMAGENEBIO INC / IMA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IMAGENEBIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to IMA.


Can you provide the valuation status for IMAGENEBIO INC?

ChartMill assigns a valuation rating of 0 / 10 to IMAGENEBIO INC (IMA). This can be considered as Overvalued.


How profitable is IMAGENEBIO INC (IMA) stock?

IMAGENEBIO INC (IMA) has a profitability rating of 1 / 10.


How financially healthy is IMAGENEBIO INC?

The financial health rating of IMAGENEBIO INC (IMA) is 7 / 10.